HMN Beats on EPS but Revenue Disappoints

Horace Mann Educators Corporation just reported Q1 2026 results with a sharp EPS beat — and a notable revenue miss — creating a rare split-verdict print right at the moment when CEO share sales have been mounting for weeks.

The earnings result is the clearest signal in this week's setup. Q1 adjusted EPS came in at $1.28, clearing the $1.09 consensus estimate by nearly 15 cents. Revenue told a different story: $429.3 million, short of the $445.4 million estimate. Management reaffirmed full-year adjusted EPS guidance of $4.20–$4.50, a range that straddles the current consensus of $4.52. Guidance at the low end of analyst estimates is rarely received as a statement of confidence, even when the headline EPS is strong. The stock closed at $45.97 on May 5 — up 6.4% over the past month — but trading has been roughly flat this week.

The insider picture adds texture to the question of conviction. CEO Marita Zuraitis sold 7,081 shares across two transactions on May 1 and May 4, collecting roughly $327,000 at prices near $46.16. She also sold 7,500 shares on April 23 for around $346,000. Total net insider selling over the past 90 days runs to approximately $876,000 in value, even after a March equity award of over 63,000 shares to Zuraitis and stock grants across the executive team. The awards dilute the bearish read on these sales somewhat — executives typically diversify after awards — but the timing, just ahead of earnings, keeps the pattern worth noting. The significance scores on individual trades are modest, registering 2 out of 10, suggesting these are routine-sized transactions rather than dramatic signals. Still, the volume of CEO sales in the run-up to a print that carries a revenue miss warrants attention.

The broader positioning picture is low-key. Short interest is modest at 2.1% of the free float, with roughly 866,000 shares short — well off a near-term peak above 895,000 in late April. Borrow conditions have eased considerably. Cost to borrow dropped to 0.54% from above 1.2% a week ago, a roughly 48% decline, making this one of the cheapest borrows in the multi-line insurance space. Borrow availability is very loose, meaning there is no meaningful squeeze risk in the lending market. The ORTEX short score is 33.5 — comfortably below the midpoint — and has barely moved over the past two weeks. The lending market is not a story here.

The Street consensus is an isolated "hold," with a mean price target around $51.50 — implying roughly 12% upside to the current price. The most recent substantive analyst action dates to mid-2025: BMO Capital initiated with an Outperform at $48, while Piper Sandler and Raymond James were raising targets, also in 2025. No analyst has moved on the name in 2026 as yet, so the post-earnings note flow in the coming days will be the first real read on how the Street reacts to the EPS beat against the revenue shortfall and the guidance straddle. The P/E ratio is running near 9.5x — not a demanding valuation for a niche insurer with improving margins. The company's P/B of 1.09x is similarly undemanding. Factor scores on EPS momentum are soft: the 30-day reading ranks in just the 32nd percentile. That aligns with a company beating a low bar rather than one where earnings revisions are accelerating.

What to watch is simple: the analyst response to Q1 in the next 48 hours. The beat-on-EPS, miss-on-revenue combination alongside guidance that sits below consensus sets up a debate between those who see margin improvement as the durable story and those who view revenue shortfall and soft forward guidance as an obstacle to further re-rating from current levels.